Ethical Scenario: Cardiovascular System

Slides:



Advertisements
Similar presentations
EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.
Advertisements

New Atrial Fibrillation/Flutter Pathway and GRASP Tool
SMASH-VT Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Vivek Reddy Substrate Mapping and Ablation in Sinus Rhythm to Halt.
Myocardial Repair by Percutaneous Cell Transplantation of Autologous Skeletal Myoblast as a Stand Alone Procedure in Post Myocardial Infarction Chronic.
Brugada’s Syndrome and Sudden Cardiac Death
Cardiovascular Disaster in Hemodialysis patients
Ventricular Tachycardia
Implantable Cardioverter Defibrillators to Prevent Sudden Cardiac Death: Background Frederick A. Masoudi, MD, MSPH Associate Professor of Medicine (Cardiology)
Thursday 4/12/2014 Hassan Alahmadi Medical Resident ( R1)
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
PACT Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.
Implantable Cardioverter Defibrillator Rebecca Boduch Biomedical Engineering University of Rhode Island.
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Indications of ICD in 2010 Dr Mervat Aboulmaaty Professor of Cardiology Ain Shams University DAF 1 st EP course 2010.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Arrhytmia In Heart Failure
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Mr. J is a 70 year old man with an ischemic cardiomyopathy who presents with class III CHF and significant dissatisfaction with his functional capacity.
2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults p.o.box zip code Done by: Dr.Amin Zagzoog.
Heart Failure: From Failure to Success
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
EP Show – Aug 2003 ICDs – Primary prevention The EP Show: Which ICD for which patient? Part 2: Primary prevention Eric Prystowsky MD Director, Clinical.
Atrial Fibrillation Andreas Stein Robert Smith, M.D. August 11, 2003.
Ventriclar Tachycardia
Cardiac Intervention in the Elderly. Cardiac Interventions Coronary Artery Bypass Grafting (CABG) Percutaneous Transluminal Coronary Angioplasty (PTCA)
Devices and the older patient with syncope Michael Gammage, Reader in Cardiovascular Medicine MHRA Committee for Safety of Devices.
EP Show – Aug 2003 ICDs – Secondary prevention The EP Show: Which ICD for which patient? Part 1: Secondary prevention Eric Prystowsky MD Director, Clinical.
ARRHYTHMIA. Disturbance of cardiac rythumn Anatomy of the conducting system.
EP show – June 2004 EP show The EP show: Risk stratification for sudden death Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent.
EP Show – Dec 2003 ICDs – Primary prevention The EP Show: Guidelines and reimbursement at the crossroads: Primary prevention with ICDs Eric Prystowsky.
Adult with operated congenital heart disease: what should we check for? January 15 th, h-17h30.
© 2008, American Heart Association. All rights reserved. AHA/ACC/HRS Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Approach to Palpitations
Implantable Cardioverter Defibrillator (ICD) Reprogramming Guidelines Lauren Butler.
THE HEART’S ELECTRICAL SYSTEM Marco Perez, MD Center for Inherited Cardiovascular Disease Inherited Cardiac Arrhythmia Clinic June 20, 2013.
Ventricular Arrhythmias:A General Cardiologist’s Assessment of Therapies in 2004 C.Richard Conti M.D. MACC.
Date of download: 7/10/2016 From: Potential Cost-Effectiveness of Prophylactic Use of the Implantable Cardioverter Defibrillator or Amiodarone after Myocardial.
Sudden Cardiac Arrest Morhaf Ibrahim, MD, FHRS Electrophysiology.
Fig ACCF/AHA Guideline for the management of heart failure
Implantable Defibrillator Therapy Post Cardiac Arrest
Right ventricular disarticulation for arrythmogenic right ventricular dysplasia: an 18 year single centre experience. J Zacharias, J Forty, C Doig*, J.
Atrial Fibrillation: When Should You Consider Ablation?
Simon A. Castro, MD; Daniele Muser, MD; Erica Zado, PA; Rajeev K
American College of Cardiology Presented by Dr. Stuart J. Connolly
Deactivating the shocking component of an Implantable Cardioverter Defibrillator (ICD) (When no longer appropriate)
Pacemakers and Implantable Cardioverter-Defibrillators
Brugada’s Syndrome and Sudden Cardiac Death
Arrhythmogenic right ventricular dysplasia
Preventing SCD With a WCD: Reviewing the Results of the VEST Trial
HYPERTROPHIC CARDIOMYOPATHY(HCM)
The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.
The most common cause of death in North America is cardiac death and the most common cause of cardiac death is sudden death from ventricular arrhythmias.
The EP show: sudden death, part 1 Director
Patients with implantable defibrillators are out there and coming your way
Noriko Kikuchi et al. JACEP 2016;2:
Volume 15, Issue 10, Pages e190-e252 (October 2018)
Volume 15, Issue 10, Pages e73-e189 (October 2018)
Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines  Matthew Bennett, MD (Co-Chair),
Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology,
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
ΝΟΣΟΣ ΤΑΧΥΒΡΑΔΥΚΑΡΔΙΑΣ: ΕΜΦΥΤΕΥΣΗ ΒΗΜΑΤΟΔΟΤΗ Η ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ ; ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ ΕΠ.Α ΚΑΡΔΙΟΛΟΓΟΣ ΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ.
David F. Katz et al. JACEP 2016;j.jacep
Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.
Outcomes After Ventricular Fibrillation Out-of-Hospital Cardiac Arrest: Expanding the Chain of Survival  T. Jared Bunch, MD, Stephen C. Hammill, MD, Roger.
David F. Katz et al. JACEP 2017;3:20-28
Jordan S. Leyton-Mange et al. JACEP 2017;j.jacep
Diagnosis at presentation and diagnoses finally reached at the end of the inpatient admission. Diagnosis at presentation and diagnoses finally reached.
Stepwise treatment of patients with symptomatic (NYHA II–IV) heart failure with reduced ejection fraction. Stepwise treatment of patients with symptomatic.
Survival free of atrial fibrillation after implantation of an implantable cardioverter defibrillator in our series (151 patients): overall population (solid.
Presentation transcript:

Ethical Scenario: Cardiovascular System ST2 Group 20/7/11 Ethical Scenario: Cardiovascular System

GP Commissioning Scenario You have decided to take the plunge and join a GP commissioning consortium. Within a few weeks of starting the job you are required to make a high profile budget decision. The local hospital trust has increased it’s spending on 2 significant areas within cardiology – ICD implantation and cardiac ablation. ICD implantation has been proven to prolong life as well as potentially improve quality of life. It is used mainly for older adults who have a history of VT or severe left ventricular dysfunction. The cost of the device is £20000, but the treatment cost over 5 years (device changes, hospital treatment and investigation, prolonged life ) amounts to £70000. The life expectancy after implantation is around 5 years. Cardiac ablation is generally used for patients with AF and a reduced quality of life (normally younger/active patients) who have not responded well to conservative treatment. The costs of cardiac ablation are around £5000 per patient, but many more would be eligible than for ICD devices. There is also evidence that it improves survival compared to drug treatment.

GP Commissioning Scenario Unfortunately you have inherited a large amount of debt from the PCT, and are being asked to reduce costs through efficiency savings. You think that you may be able to increase the spending on one of the procedures, but only through withdrawing funding for the other. A local pressure group called ‘Heart to Heart’, tipped off by a local Cardiologist, has brought this dilemma to the attention of the media. A press conference has been organised for you to announce your decision. Your options seem to be to increase funding for one procedure while stopping the other, not to increase funding for either, or to try and fund an increase in both by making cuts elsewhere.

GP commissioning scenario Divide into 2 groups – the consortium and the press. The consortium group needs to prepare a decision and their justification/reasoning, then elect one or more spokesperson/s. The media group should plan out their lines of questioning for the different outcomes- remember you need to get a sensational story! A third group could be activists from ‘Heart to Heart’ who have been picketing outside the hall, and have managed to sneak into the conference.

NICE ICD implantation guidance 1.1. The use of implantable cardioverter defibrillators (ICDs) should be routinely considered for patients in the following categories: 1.1.1 ‘Secondary prevention’ i.e. for patients who present, in the absence of a treatable cause, with:- • Cardiac arrest due to either ventricular tachycardia (VT) or ventricular fibrillation (VF) • Spontaneous sustained VT causing syncope or significant haemodynamic compromise • Sustained VT without syncope/cardiac arrest, and who have an associated reduction in ejection fraction (less than 35%) but are no worse than class 3 of the New York Heart Association functional classification of heart failure. 1.1.2 ‘Primary prevention’ for patients (see paragraph 2.5 for definition) with: • a history of previous myocardial infarction (MI) and all of the following: i) non sustained VT on Holter (24 hour ECG) monitoring; ii) inducible VT on electrophysiological testing; iii) left ventricular dysfunction with an ejection fraction (EF) less than 35% and no worse than class III of the New York Heart Association functional classification of heart failure. • a familial cardiac condition with a high risk of sudden death, including long QT syndrome, hypertrophic cardiomyopathy, Brugada syndrome, arrhythmogenic right ventricular dysplasia (ARVD) and following repair of Tetralogy of Fallot.

NICE radiofrequency ablation guidance: Extracts 2.1.4 Percutaneous radiofrequency ablation is a treatment option for symptomatic patients with atrial fibrillation refractory to anti-arrhythmic drug therapy or where medical therapy is contraindicated because of co-morbidity or intolerance. 2.3.2 In a non-randomised comparative study of 1171 patients, 78% of patients treated with radiofrequency ablation were estimated to be free of atrial fibrillation at 3 years, compared with 37% of patients treated with medication (p < 0.001). Patients receiving percutaneous radiofrequency ablation had a 54% reduction in risk of death compared with those receiving medication (p < 0.001).